Johnson & Johnson's Q1 2024 earnings call highlighted strong financial results and significant pipeline advancements, particularly in oncology and MedTech.  Positive guidance updates and robust R&D investments suggest continued growth potential.  The acquisition of Shockwave Medical further strengthens the company's position in cardiovascular, thus potentially boosting stock price in the short term.
[2]
